New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

Angina, a symptom of underlying heart disease, is frequently overlooked in women despite being a leading cause of death.

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

Spotting ILDs may be challenging. Symptoms such as a dry cough, shortness of breath, and unexplained weight loss may go ...

October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...

If men felt the way we do two weeks of the month, scientists would be working around the clock to solve their suffering. But ...

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...

At the LifeBridge Health ENT Sinus & Allergy Center, Dr. Alpen Patel helps patients get to the root of disrupted sleep. With ...

There are steps physicians can take to prepare their patients with pulmonary issues for the changing of the seasons.

Nirmatrelvir-ritonavir reduced the risk for long COVID in adults aged 50 years and older but not in adolescents.

FDA accepts Achieve Life Sciences' NDA for cytisinicline in smoking cessation. Promising vaping results boost market ...

Reckitt, the maker of Mucinex®, the #1 physician-trusted cough and cold brand*, announced new outcomes from the Guaifenesin Assessment of Satisfaction for Patients (GASP) Study, the first long-term ...